French molecular imaging firm Advanced Accelerator Applications (AAA) has received approval from Health Canada to market its Lutathera (lutetium-177 DOTATATE) therapeutic agent for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults with progressive disease.
NETs are rare tumors that originate in the neuroendocrine cells of numerous organs, and they are most commonly found in the lungs, gastrointestinal tract, and pancreas. Because the symptoms of NETs can mimic those of other conditions, patients with NETs are often misdiagnosed. By the time NETs are correctly diagnosed, the cancer has often metastasized to other parts of the body.
AAA is currently determining when Lutathera will be available in Canada.
